Original Title: Several Policy Measures to Promote the High-Quality Development of the City’s Biopharmaceutical Industry

To thoroughly implement the guiding principles of the Provincial Government’s document “Several Policy Measures to Promote the High-Quality Development of the Provincial Biomedical Industry,” carry out the work arrangements regarding the development of the biomedical industry as outlined in the 15th Municipal Party Congress, and fully advance the open innovation and high-quality development of the city’s entire biomedical industry chain, the following policy measures are hereby proposed.

I. Defining Industrial Development Goals

1. Overall Objectives. Building on Nanjing’s advantages in science and education resources and its industrial foundation, we will focus on key areas such as gene and cell therapy, biopharmaceuticals, and in vitro diagnostics to accelerate industrial clustering.By 2025, the scale of the biopharmaceutical industry will strive to exceed 240 billion yuan, with comprehensive innovation capabilities ranking among the top tier nationally, and a cluster-based development pattern will be preliminarily established; several leading enterprises will be cultivated, with five enterprises reaching a scale of 5 billion yuan or more, and full coverage and synergy of key biopharmaceutical infrastructure and public services will be achieved.

II. Enhancing R&D and Innovation Capabilities

2. Continuously advance the construction of major innovation platforms. Focusing on key areas such as gene and cell therapy, biopharmaceuticals, and in vitro diagnostics, fully leverage the role of basic and applied research platforms to vigorously promote the R&D of original drugs, innovative drugs, and high-end medical devices. Support innovation platforms in undertaking provincial and national-level major projects as well as projects along the industrial chain, and strive to establish provincial and national-level innovation platforms. (Responsible Units: Municipal Science and Technology Bureau; Jiangbei New Area, Jiangning District, Xuanwu District, Gulou District, Qixia District)

3. Strengthen scientific and technological research efforts. Encourage original innovation, support basic research, applied translation, and research on common issues within the industrial chain, and promote integrated innovation among industry, academia, and research institutions. Encourage leading enterprises and research institutes to undertake provincial-level research tasks and make efficient use of municipal-level life sciences and health special funds. For projects involving major technological breakthroughs—such as common technologies across the industrial chain and upstream key core materials—implementation will be organized through a “joint research” approach, with phased funding support of up to 10 million yuan;For general projects involving preclinical technological breakthroughs, funding of up to 2 million yuan per project will be provided on a competitive basis to the most deserving candidates; for multicenter clinical trial projects, funding of up to 1 million yuan per project will be provided to the most deserving candidates; for medical-engineering collaboration projects jointly undertaken by hospitals and enterprises, funding of up to 1 million yuan per project will be provided to the most deserving candidates. (Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau, Jiangbei New Area, and all districts)

4. Support for Innovative Drug R&D. For nationally classified Class 1 new drugs, Class 2 new drugs, and biosimilars registered in our city that have completed Phase I, II, or III clinical trials, one-time rewards of up to 5 million yuan will be granted based on the specific R&D stage and on a merit-based selection. The annual reward amount for a single enterprise shall not exceed 10 million yuan. (Responsible Units: Municipal Science and Technology Bureau, Municipal Finance Bureau, Nanjing Inspection Branch of the Provincial Drug Administration)

5. Support the industrialization of innovative drugs and high-end medical devices. Projects that obtain a national registration certificate for innovative drugs or medical devices for the first time and are industrialized within the city will be granted a one-time reward. Specifically, a maximum reward of 10 million yuan will be granted per variety for National Class 1 new drugs, 5 million yuan per variety for National Class 2 new drugs, and 2 million yuan per variety for National Class 3 new drugs;Innovative medical devices (obtained through the special approval channel) will receive a maximum reward of 3 million yuan per item, while other Class III medical devices will receive a maximum reward of 1 million yuan per item. The annual reward amount for a single enterprise shall not exceed 10 million yuan. (Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Finance Bureau, Nanjing Inspection Branch of the Provincial Drug Administration)

III. Improving Clinical Research and Application

6. Promote the construction of clinical research support platforms. Integrate medical information resources such as the city’s clinical biobank to establish an open and shared digital clinical research resource service platform. Advance the construction of the National Health and Medical Big Data (Eastern) Center to achieve the sharing of health and medical resources, cross-regional data collection, data exchange, and scientific utilization. Research and formulate standardized procedures for the de-identification and use of medical and health data, and build a city-wide medical big data service platform to provide data services and support for innovation and R&D along the industrial chain, as well as application scenarios.Continue to advance the construction of clinical medical research centers and plan for the establishment of high-level biosafety laboratories. Support enterprises and institutions in Nanjing in building new drug clinical research platforms that comply with international GCP standards. (Responsible Units: Municipal Health Commission, Municipal Big Data Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Municipal Science and Technology Bureau, Jiangbei New Area)

7. Enhance the capacity for industry-medical integration and innovation. Encourage and support qualified healthcare institutions to establish research-oriented hospitals or model research wards that integrate “industry, medicine, research, and application.” Support research-oriented hospitals in piloting the production of in-house in vitro diagnostic reagents and expanding the compassionate use of investigational drugs. Support universities, research institutes, and healthcare institutions in collaborating with social entities to jointly build technology transfer platforms such as translational medicine research institutes, and construct a life and health industry ecosystem around Wutai Mountain.Support medical institutions in exploring the establishment of platforms for scientific and technological achievements (intellectual property/intangible assets). Advance mechanisms for clinical trial matching to bridge the needs and resources of enterprises and hospitals, thereby improving the quality and efficiency of industry-medical integration. (Responsible Units: Municipal Health Commission, Municipal Science and Technology Bureau, Gulou District)

8. Encourage drug clinical research and the transformation of research outcomes. For hospitals that have obtained clinical trial institution qualifications, the number of beds available for clinical research shall be no less than 30, increasing annually by no less than 30%. By 2024, the proportion of clinical research beds to the total authorized bed capacity of the hospital shall be increased to approximately 10%.Designated research wards may be excluded from calculations of the hospital’s average length of stay, bed turnover rate, bed occupancy rate, and related costs. For medical personnel who make significant contributions to the translation of clinical research outcomes, cash rewards from the commercialization of their scientific and technological achievements may be included in their unit’s annual performance-based wage total; such rewards are exempt from total limits and are not counted toward the total wage base. (Responsible Units: Municipal Health Commission, Municipal Medical Insurance Bureau, Municipal Human Resources and Social Security Bureau, Municipal Science and Technology Bureau)

9. Promote mutual recognition of clinical trial ethics reviews. Consolidate the achievements of the city-wide clinical research ethics review alliance, promote multi-center clinical research ethics review collaboration, and accelerate the development of the Nanjing Ethics Review Information Platform.Encourage more high-level clinical trial institutions—especially those capable of undertaking multi-center clinical trial projects—to join the alliance, further tapping into the potential for clinical resource transformation in our city; further seek support from the Provincial Health Commission to extend mutual recognition of ethical reviews to other cities within the province and the Yangtze River Delta region, thereby enhancing Nanjing’s capacity to aggregate clinical resources and creating better conditions for pharmaceutical companies to develop new drugs. (Responsible Units: Municipal Health Commission, Municipal Science and Technology Bureau, Gulou District, Xuanwu District)

10. Accelerate the application and promotion of innovative biopharmaceutical products. Support the accelerated online listing and market launch of innovative products, and actively recommend that innovative products from our city’s pharmaceutical enterprises be included in the National Medical Insurance Directory. Further improve medical insurance support measures for the promotion and use of innovative biopharmaceutical products, and promote the use of innovative products in medical institutions within our city, provided that clinical needs are met and relevant regulations are complied with. (Responsible Units: Municipal Medical Insurance Bureau, Municipal Health Commission, Nanjing Inspection Branch of the Provincial Drug Administration)

11. Encourage the expansion into overseas markets. Guide enterprises to actively apply for clinical trial approvals and overseas marketing authorizations for drugs and medical devices from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceutical and Medical Devices Agency (PMDA) of Japan, and to implement industrialization within our city for export to international markets. Encourage relevant districts to introduce supporting policies. (Responsible Units: Municipal Bureau of Industry and Information Technology, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area, and all districts)

IV. Optimizing Review and Approval Services for Pharmaceuticals and Medical Devices

12. Enhance the efficiency of review and approval services. Improve the efficiency of review and approval for matters under municipal jurisdiction; establish a “green channel” for the registration and approval of pharmaceutical and medical device enterprises; streamline application materials and shorten approval timelines. Accelerate the construction of the Nanjing Sub-center and Jiangbei Branch of the Provincial Drug Administration’s Review and Inspection Division, and leverage the functions of the Gaochun Workstation of the Provincial Drug Administration’s Review and Inspection Division and the Gaochun Laboratory of the Provincial Medical Device Testing Institute.Optimize market access standards for pharmaceutical and medical device distribution enterprises, and support mergers, reorganizations, and collaborative innovation among various types of such enterprises. Implement a “single inspection covering multiple requirements” approach, including consolidated inspections, inspection exemptions, and mutual recognition of inspection results, to facilitate the submission of innovative drug and medical device applications and on-site inspections. (Responsible Units: Municipal Market Regulation Bureau, Nanjing Inspection Branch of the Provincial Drug Administration)

13. Strengthen efficient follow-up services. Establish an early intervention mechanism for key products such as innovative drugs and medical devices, enhance communication and coordination with the National and Provincial Drug Administration, and provide professional guidance on regulations, policies, and technology. Encourage and support industrial parks in establishing specialized service teams with drug and medical device review and inspection capabilities, cultivate registration application service specialists, and provide regular consultation services to enterprises to resolve bottlenecks and challenges in project development.(Responsible Units: Nanjing Inspection Branch of the Provincial Drug Administration, Municipal Market Regulation Bureau, Jiangbei New Area, and all districts)

14. Promote the development of testing and inspection service platforms. Establish a municipal technical platform for testing and inspection services in the biopharmaceutical industry, expand the scope of registration testing, and shorten testing cycles.Improve CNAS, CMA, and CAL testing qualifications for cosmetics and establish a technical review support platform for cosmetics. Support the construction of the Biometrics Testing Center in the Nanjing Area of the China (Jiangsu) Pilot Free Trade Zone, coordinate with the Provincial Drug Administration to apply to the National Medical Products Administration for medical device testing and inspection qualifications, and provide enterprises with medical device testing, inspection, and technical consulting services to further shorten the testing cycle for medical device product registration.High-quality efforts will be made to complete and put into operation the testing laboratory of the Gaochun Branch of the Provincial Medical Device Testing Institute. Support will be provided for the construction of the Provincial Drug Administration’s training center and the Jiangsu Medical Device Big Data Center, with preferential policies offered in areas such as human resources and infrastructure. Vigorously develop third-party testing and inspection service agencies, prioritizing their establishment in areas where public service platform resources are concentrated, such as the Nanjing Area of the China (Jiangsu) Pilot Free Trade Zone. (Responsible Units: Municipal Market Regulation Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area, Gaochun District)

V. Enhancing the Stability and Competitiveness of Industrial and Supply Chains

15. Strengthen the Attraction and Cultivation of Leading Enterprises. Adhere to a strategy that combines cultivation with attraction, intensify investment promotion efforts, and support and encourage global benchmark biopharmaceutical companies to establish regional headquarters, R&D centers, and production bases in Nanjing.Implement a tiered enterprise cultivation plan to establish a tiered cultivation database comprising leading enterprises under cultivation, enterprises on the verge of breakthroughs, and enterprises with development potential. Establish a key tracking and service mechanism to provide targeted support for promising products with good market prospects, leading technology, and independent intellectual property rights—covering drug screening, preclinical evaluation, clinical trials, registration and approval, and market launch—to foster a group of technology-leading and market-dominant leading enterprises.(Responsible Units: Municipal Science and Technology Bureau, Municipal Investment Promotion Bureau, Municipal Commerce Bureau, Zitou Group, Jiangbei New Area, and all districts)

16. Strengthen the supply security of key materials. Support eligible regions in planning and constructing green production bases for active pharmaceutical ingredients (APIs), industrial clusters for biological reagents, and high-end manufacturing centers for key raw materials, high-end excipients, and critical consumables in the biopharmaceutical sector. Implement specialized work mechanisms—including dedicated safety assessments, specialized environmental impact evaluations, specialized drug review services, and on-site regulatory supervision—to provide biopharmaceutical enterprises with small-batch, low-cost, and customized supplies of key materials.Explore and refine mechanisms for cooperation and profit-sharing in the R&D and production of pharmaceutical intermediates and APIs with eligible regions to meet the production needs of our city’s biopharmaceutical enterprises. (Responsible Units: Municipal Science and Technology Bureau, Municipal Industry and Information Technology Bureau, Municipal Ecology and Environment Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area, Jiangning District, Qixia District)

17. Promote new models of R&D and production organization. Encourage the outsourcing of R&D and production activities through Contract Manufacturing Organizations (CMOs) or Contract Development and Manufacturing Organizations (CDMOs), and encourage enterprises to undertake contract manufacturing for domestic Marketing Authorization Holders (MAHs). Encourage relevant districts to introduce supportive policies to enhance production service capabilities. (Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Bureau of Science and Technology, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area, and all districts)

18. Strengthen public technical services. Focusing on the needs of industrial development, build a comprehensive public technical service system covering key links in the industrial chain, such as gene sequencing, new drug testing, high-end medical devices, biotechnology, preclinical services, and R&D of novel formulations. Continue to advance the construction of generic manufacturing platforms and public service platforms, and encourage the establishment of essential platforms currently lacking in the industry, such as formulation research, laboratory animal facilities, and CRO services. (Responsible Units: Municipal Science and Technology Bureau, Jiangbei New Area, and all districts)

19. Optimize environmental access management for the biopharmaceutical sector. For eligible specialized pharmaceutical parks, accelerate the integration of planning environmental impact assessments with project-specific assessments and streamline the environmental impact assessment process. Major provincial and municipal pharmaceutical industry projects shall benefit from a green approval channel; provided the transfer conditions are met, total pollutant emission quotas may be allocated and adjusted across the city.While ensuring environmental quality in industrial clusters, explore the prioritization of nitrogen, phosphorus, and other emission quotas reduced from other industries across the city for pharmaceutical projects. Encourage specialized biopharmaceutical industrial parks to develop “Green Island” projects for pollution control measures, thereby enhancing the centralization and specialization of pollution prevention and control, and reducing pollution treatment costs for small and medium-sized biopharmaceutical enterprises. (Responsible Units: Municipal Ecology and Environment Bureau, Municipal Development and Reform Commission)

20. Strengthen land and spatial resource support. Prioritize support for major industrial projects, promote the concentration of land resources toward the biopharmaceutical industry, and ensure the smooth implementation of high-quality projects. Determine land transfer methods and lease terms based on the enterprise life cycle to effectively reduce land costs for enterprises, optimize industrial spatial layout, and improve land use efficiency. (Responsible Units: Municipal Planning and Natural Resources Bureau, Municipal Industry and Information Technology Bureau)

21. Promote the digital transformation of the biopharmaceutical industry. Continuously advance the digital and intelligent transformation of biopharmaceutical manufacturing enterprises and improve the new “Future Factory” system for the biopharmaceutical industry. Integrate upstream and downstream industrial and supply chains to enhance collaboration efficiency within the industrial chain and the level of integrated coordination in the supply chain. Promote the deep integration of next-generation information technology with the biopharmaceutical industry, accelerate the use of artificial intelligence to empower innovation and R&D, and elevate the level of intelligent and automated production across the industrial chain. (Responsible Units: Municipal Bureau of Industry and Information Technology, Municipal Bureau of Big Data, Municipal Bureau of Science and Technology, Jiangbei New Area, and all districts)

VI. Building a Hub for Biopharmaceutical Innovation Talent

22. Intensify efforts to attract high-level biopharmaceutical talent. Support the recruitment of world-class talent and teams by implementing a “fast-track” system for talent program applications, handling each case on its own merits and providing special treatment where warranted; eligible candidates will be prioritized for inclusion in the Purple Mountain Talent Summit Program.For leading scientific and technological talents tackling “bottleneck” critical core technologies, prioritize their inclusion in the Purple Mountain Talents Pioneer Plan and the Advanced-Stage Summit Plan, and provide up to 10 million yuan in matching funds for the industrialization of research outcomes. Strengthen incentives for high-level biomedical talent, and award units and individuals who make outstanding contributions in accordance with relevant regulations. (Responsible Units: Municipal Party Committee Organization Department, Municipal Finance Bureau)

23. Support the development of outstanding young talent in the biomedicine sector. Support key biomedicine enterprises in establishing postdoctoral research stations, and give priority to postdoctoral researchers at these stations when applying for postdoctoral funding programs at all levels.A fast-track process will be established for postdoctoral professionals’ professional title evaluations. Postdoctoral researchers currently in residence may directly apply for evaluation and recognition of senior professional titles; those holding associate senior titles may directly apply for evaluation and recognition of full senior titles, with research achievements during their residency serving as a key basis for evaluation. Postdoctoral researchers who have completed their residency and have worked for at least one year in professional technical positions such as teaching or research, demonstrating outstanding performance, will be given priority for promotion to the next higher professional title under equal conditions and will be given priority for appointment to corresponding professional technical positions.In the professional title evaluation of talent in the biomedicine sector, explore increasing the weighting of performance scores for professional academic activities and clinical drug R&D. For full-time doctoral graduates from the world’s top 200 universities who come to Nanjing to work in the biomedicine sector, those who meet the criteria will be recommended for the Provincial “Double Innovation” Doctor program and receive financial subsidies. Organize specialized recruitment events for the biomedicine sector to attract more recent graduates from relevant majors at Nanjing-based universities to stay and develop their careers in the city. (Responsible Units: Municipal Party Committee Organization Department, Municipal Human Resources and Social Security Bureau, Municipal Finance Bureau)

24. Jointly cultivate specialized technical talent in the biomedical sector. Intensify efforts to train high-skilled personnel for key manufacturing positions such as pharmaceutical testing, inspection, and quality control, and encourage enterprises to adopt new apprenticeship systems, modern apprenticeship systems, and customized training programs. Strengthen vocational education and skills training, and support enterprises in collaborating with universities, research institutes, and medical institutions to establish biomedical applied technology education and practical training bases. (Responsible Units: Municipal Human Resources and Social Security Bureau, Municipal Education Bureau)

VII. Building a Favorable Industrial Ecosystem

25. Support open innovation across the entire industrial chain. Actively seek national and provincial support to enable the Nanjing Area of the China (Jiangsu) Pilot Free Trade Zone to pioneer initiatives in the construction of major innovation platforms, reform of drug and medical device review and approval systems, expansion of openness in the medical services sector, and capacity building for drug regulation. The Nanjing Drug Import Port will actively seek to expand its functions to include a “biological product import port.”(Responsible Units: Municipal Bureau of Commerce, Jinling Customs, Municipal Market Regulation Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area)

26. Enhance customs clearance efficiency for the biopharmaceutical sector. Establish a specialized directory of entities engaged in R&D, production, and sales within the biopharmaceutical sector that involve import and export operations, conduct credit cultivation initiatives, and grant customs clearance conveniences based on credit ratings. Support the Nanjing Area of the Pilot Free Trade Zone in establishing high-standard institutions such as the centralized supervision and public service platform for biopharmaceuticals and the Nanjing Risk Assessment Service Center for Special Import/Export Items, and support the application to establish a comprehensive bonded zone in the Nanjing Area to enhance the functionality of open platforms.Seek to pilot the following procedures within the Pilot Free Trade Zone: approval for one-time imports of reference drugs for research purposes, renewal of drug production/operating licenses, and issuance of operating licenses for headquarters of retail drug chains. (Responsible Units: Municipal Bureau of Commerce, Jinling Customs, Municipal Market Regulation Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Jiangbei New Area)

27. Leverage the roles of industry alliances and high-end exhibitions. Fully utilize Nanjing’s talent advantages and effectively harness the functions of the Nanjing Biomedical Industry Expert Database, the Jiangsu Industrial Technology Research Institute, the Nanjing New Medicine and Life Health Industry Innovation Service Alliance, and the Nanjing Biomedical Industry Innovation Investment Promotion Association as bridges, links, and think tank platforms. Support the introduction, planning, and organization of international, national, and specialized industrial exhibitions, summits, forums, and academic exchange activities.Encourage industrial parks to host innovation and entrepreneurship competitions, project roadshows, industry salons, and other events that align with their respective industrial characteristics. (Responsible Units: Municipal Science and Technology Bureau, Municipal Investment Promotion Bureau, Municipal Commerce Bureau, Zitou Group, Jiangbei New Area, and all districts)

28. Strengthen management services for human genetic resources. Establish a service window for human genetic resource management to provide consultation, services, training, and research on human genetic resource management, and assist national and provincial human genetic resource management agencies in conducting ex-post supervision of human genetic resource activities. (Responsible Units: Municipal Science and Technology Bureau, Jiangbei New Area)

29. Strengthen collaborative intellectual property protection. Leverage the supporting role of the Nanjing Intellectual Property Protection Center (Platform) to provide a “green channel” for patent fast-track examination, rapid rights confirmation, and expedited rights enforcement to enterprises in the biopharmaceutical industry. Support the development of the Nanjing Biopharmaceutical Industry Intellectual Property Protection Alliance, promote collaborative efforts among enterprises in intellectual property creation, utilization, and protection, and accelerate the cultivation of a portfolio of high-value patents that support and lead industrial development. (Responsible units: Municipal Market Regulation Bureau)

30. Forge the “Nanjing Manufacturing” quality brand. Thoroughly implement Good Manufacturing Practices (GMP) for pharmaceuticals and medical devices, strengthen the exchange of risk information with enterprises, and guide enterprises to continuously improve their quality management systems. Implement standard-led development by supporting qualified biomedical entities to participate in the formulation of international, national, and industry standards, and encourage enterprises to actively undertake national and provincial standardization pilot projects.Refine incentive policies for quality and branding, encouraging leading pharmaceutical enterprises, industry benchmark enterprises, and “specialized, refined, distinctive, and innovative” small giant enterprises to compete for government quality awards, create “Jiangsu Premium Products,” and cultivate a group of quality demonstration enterprises. Strictly crack down on illegal activities such as the production and sale of counterfeit and substandard products to foster a fair and orderly market competition environment. (Responsible units: Municipal Market Regulation Bureau, Nanjing Inspection Branch of the Provincial Drug Administration)

31. Strengthen financial support. Support enterprises in integrating their strengths and pursuing mergers and reorganizations. Explore new financing models for the biopharmaceutical sector, such as intellectual property securitization. Support eligible biopharmaceutical enterprises in raising capital directly through initial public offerings (IPOs) and bond issuances. Encourage various insurance institutions in Nanjing to provide customized comprehensive insurance products, such as liability insurance for biopharmaceutical human clinical trials and product liability insurance, and to innovate by establishing fast-track claims settlement channels for specialized insurance products in the pharmaceutical industry.Leverage the supportive role of government investment funds and venture capital funds to support pharmaceutical R&D and the commercialization of research outcomes. (Responsible Units: Municipal Financial Regulatory Bureau, Municipal State-owned Assets Supervision and Administration Commission, Municipal Bureau of Industry and Information Technology, Municipal Market Regulation Bureau, Municipal Science and Technology Bureau, Jiangbei New Area, and all districts)

32. Establish a long-term mechanism for serving enterprises. Establish a joint conference system for the high-quality development of the municipal biopharmaceutical industry. Based on the industrial sectors corresponding to departmental functions, research and formulate relevant policies, coordinate the resolution of major issues, and promote the implementation of various tasks.All districts (development zones) and sub-districts shall fulfill their local primary responsibilities, establish “face-to-face” liaison service mechanisms, and provide follow-up services for key enterprises and projects. Based on enterprise needs, organize monthly enterprise service liaison activities to promptly resolve difficulties encountered in enterprise development, including review and approval, clinical collaboration, promotion of innovative products, investment and financing, talent recruitment, environmental access, and drug import and export.(Responsible Units: Municipal Science and Technology Bureau, Municipal Party Committee Organization Department, Municipal Industry and Information Technology Bureau, Municipal Human Resources and Social Security Bureau, Municipal Planning and Natural Resources Bureau, Municipal Ecology and Environment Bureau, Municipal Commerce Bureau, Municipal Health Commission, Municipal Market Regulation Bureau, Municipal Medical Insurance Bureau, Nanjing Inspection Branch of the Provincial Drug Administration, Jinling Customs, etc., as well as Jiangbei New Area and all districts)

These policy measures shall take effect upon issuance and remain valid until December 31, 2025. In the event of overlap with other similar policies or guidelines in our city, support shall be provided in accordance with the principle of “selecting the most favorable, applying the highest standard, and avoiding duplication.”